In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts

Biomedical Optics Express

Volumn 5, Issue 7, 2014, Pages 2247-2261

  Mccormack, Devin R ^a   Walsh, Alex J ^a   Sit, Wesley ^a   Arteaga, Carlos L ^b,c,d   Chen, Jin ^b   Cook, Rebecca S ^b,d   Skala, Melissa C ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSELS; DISEASES; OXYGENATION; SPECTROSCOPY; TUMORS;

BREAST CANCER XENOGRAFTS; DISTRIBUTION ANALYSIS; HEMOGLOBIN OXYGENATION; HYPERSPECTRAL IMAGING; IMMUNOHISTOCHEMISTRY; INITIAL TREATMENT; MICROVESSEL DENSITY; TUMOR VASCULATURE;

MONOCLONAL ANTIBODIES;

CASPASE 3; CD31 ANTIGEN; HEMOGLOBIN; IMMUNOGLOBULIN G1 ANTIBODY; KI 67 ANTIGEN; TRASTUZUMAB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD OXYGEN TENSION; BLOOD OXYGENATION; BLOOD VESSEL REACTIVITY; BREAST CANCER; CAPILLARY DENSITY; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; HYPERSPECTRAL IMAGING; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84903709007     PISSN: None     EISSN: 21567085     Source Type: Journal    
DOI: 10.1364/BOE.5.002247     Document Type: Article

References (37)

1. R. Siegel, D. Naishadham, and A. Jemal, Cancer Statistics 2013, 11-30 (2013) (doi:10.3322/caac.21166.)
2. D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and et, "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer," Science 244(4905), 707-712 (1989).
3. J. S. Ross and J. A. Fletcher, "The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy," Stem Cells 16(6), 413-428 (1998).
4. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. H. Barrios, G. Steger, C. S. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. M. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. S. Dolci, and R. D. Gelber; Herceptin Adjuvant (HERA) Trial Study Team, "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer," N. Engl. J. Med. 353(16), 1659-1672 (2005).
5. C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart, and M. Press, "Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer," J. Clin. Oncol. 20(3), 719-726 (2002).
6. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, and R. K. Jain, "Tumour biology: herceptin acts as an anti angiogenic cocktail," Nature 416(6878), 279-280 (2002).
7. R. K. Jain, "Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy," Science 307(5706), 58-62 (2005).
8. M. W. Dewhirst, "Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress," Radiat. Res. 172(6), 653-665 (2009).
9. C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart, and M. Press, "Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer," J. Clin. Oncol. 20(3), 719-726 (2002).
10. G. Valabrega, F. Montemurro, and M. Aglietta, "Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer," Ann. Oncol. 18(6), 977-984 (2007).
11. G. Shen, H. Huang, A. Zhang, T. Zhao, S. Hu, L. Cheng, J. Liu, W. Xiao, B. Ling, Q. Wu, L. Song, and W. Wei, "In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models," Cancer Immunol. Immunother. 60(3), 339-348 (2011).
12. M. E. Hardee, R. J. Eapen, Z. N. Rabbani, M. R. Dreher, J. Marks, K. L. Blackwell, and M. W. Dewhirst, "Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors," Cancer Chemother. Pharmacol. 63(2), 219-228 (2009).
13. C. Shah, T. W. Miller, S. K. Wyatt, E. T. McKinley, M. G. Olivares, V. Sanchez, D. D. Nolting, J. R. Buck, P. Zhao, M. S. Ansari, R. M. Baldwin, J. C. Gore, R. Schiff, C. L. Arteaga, and H. C. Manning, "Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer," Clin. Cancer Res. 15(14), 4712-4721 (2009).
14. C. V. Pastuskovas, E. E. Mundo, S. P. Williams, T. K. Nayak, J. Ho, S. Ulufatu, S. Clark, S. Ross, E. Cheng, K. Parsons-Reponte, G. Cain, M. Van Hoy, N. Majidy, S. Bheddah, J. dela Cruz Chuh, K. R. Kozak, N. Lewin Koh, P. Nauka, D. Bumbaca, M. Sliwkowski, J. Tibbitts, F. P. Theil, P. J. Fielder, L. A. Khawli, and C. A. Boswell, "Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model," Mol. Cancer Ther. 11(3), 752-762 (2012).
15. S. H. Park, W. K. Moon, N. Cho, J. M. Chang, S.-A. Im, I. A. Park, K. W. Kang, W. Han, and D.-Y. Noh, "Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer," Eur. Radiol. 22(1), 18-25 (2012).
16. J. F. De Los Santos, A. Cantor, K. D. Amos, A. Forero, M. Golshan, J. K. Horton, C. A. Hudis, N. M. Hylton, K. McGuire, F. Meric-Bernstam, I. M. Meszoely, R. Nanda, and E. S. Hwang, "Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017," Cancer 119(10), 1776-1783 (2013).
17. H. Degani, M. Chetrit-Dadiani, L. Bogin, and E. Furman-Haran, "Magnetic resonance imaging of tumor vasculature," Thromb. Haemost. 89(1), 25-33 (2003).
18. D. B. Jakubowski, A. E. Cerussi, F. Bevilacqua, N. Shah, D. Hsiang, J. Butler, and B. J. Tromberg, "Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study," J. Biomed. Opt. 9(1), 230-238 (2004).
19. A. Cerussi, D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J. Tromberg, "Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy," Proc. Natl. Acad. Sci. U.S.A. 104(10), 4014-4019 (2007).
20. B. S. Sorg, B. J. Moeller, O. Donovan, Y. Cao, and M. W. Dewhirst, Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development, J. Biomed. Opt. 10(4), 044004 (2005).
21. G. M. Palmer, A. N. Fontanella, S. Shan, G. Hanna, G. Zhang, C. L. Fraser, and M. W. Dewhirst, "In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters," Nat. Protoc. 6(9), 1355-1366 (2011).
22. R. D. Shonat, E. S. Wachman, W. Niu, A. P. Koretsky, and D. L. Farkas, "Near-simultaneous hemoglobin saturation and oxygen tension maps in mouse brain using an AOTF microscope," pp. 1223-1231 (1997).
23. J. A. Lee, N. M. Biel, R. T. Kozikowski, D. W. Siemann, and B. S. Sorg, "In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors," Biomed. Opt. Express 5(6), 1965 (2014).
24. K. J. Zuzak, M. D. Schaeberle, E. N. Lewis, and I. W. Levin, "Visible Reflectance Hyperspectral Imaging: Characterization of a Noninvasive, in Vivo System for Determining Tissue Perfusion," Anal. Chem. 74(9), 2021-2028 (2002).
25. A. N. Fontanella, "Novel Methods of Optical Data Analysis to Assess Radiation Responses in the Tumor Microenvironment," Duke University (2013).
26. B. J. Vakoc, R. M. Lanning, J. A. Tyrrell, T. P. Padera, L. A. Bartlett, T. Stylianopoulos, L. L. Munn, G. J. Tearney, D. Fukumura, R. K. Jain, and B. E. Bouma, "Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging," Nat. Med. 15(10), 1219-1223 (2009).
27. C. A. Ritter, M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman, and C. L. Arteaga, "Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network," Clin. Cancer Res. 13(16), 4909-4919 (2007).
28. H. C. Hendargo, R. Estrada, S. J. Chiu, C. Tomasi, S. Farsiu, and J. A. Izatt, "Automated non-rigid registration and mosaicing for robust imaging of distinct retinal capillary beds using speckle variance optical coherence tomography," Biomed. Opt. Express 4(6), 803-821 (2013).
29. P. Santago and H. D. Gage, "Quantification of MR brain images by mixture density and partial volume modeling," IEEE Trans. Med. Imaging 12(3), 566-574 (1993).
30. H. Akaike, "A new look at the statistical model identification," IEEE Trans. Automat. Contr. 19(6), 716-723 (1974).
31. A. J. Walsh, R. S. Cook, H. C. Manning, D. J. Hicks, A. Lafontant, C. L. Arteaga, and M. C. Skala, "Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer," Cancer Res. 73(20), 6164-6174 (2013).
32. G. Brockhoff, B. Heckel, E. Schmidt-Bruecken, M. Plander, F. Hofstaedter, A. Vollmann, and S. Diermeier, "Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation," Cell Prolif. 40(4), 488-507 (2007).
33. G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash, "Vascular-specific growth factors and blood vessel formation," Nature 407(6801), 242-248 (2000).
34. J. O. A. Forsythe, B. Jiang, N. V Iyer, F. Agani, and S. W. Leung, "Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1" (1996).
35. M. Potente, H. Gerhardt, and P. Carmeliet, "Basic and therapeutic aspects of angiogenesis," Cell 146(6), 873 887 (2011)
36. K. Vishwanath, H. Yuan, W. T. Barry, M. W. Dewhirst, and N. Ramanujam, "Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors," Neoplasia 11(9), 889-900 (2009).
37. T. D. O'Sullivan, A. Leproux, J.-H. Chen, S. Bahri, A. Matlock, D. Roblyer, C. E. McLaren, W.-P. Chen, A. E. Cerussi, M. Y. Su, and B. J. Tromberg, "Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy," Breast Cancer Res. 15(1), R14 (2013).